Reni Benjamin
Stock Analyst at JMP Securities
(1.34)
# 2,897
Out of 4,667 analysts
150
Total ratings
32.69%
Success rate
-11.15%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Reni Benjamin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BPMC Blueprint Medicines | Reiterates: Market Outperform | $125 | $96.11 | +30.06% | 17 | Nov 18, 2024 | |
| SANA Sana Biotechnology | Downgrades: Market Perform | n/a | $2.41 | - | 4 | Nov 5, 2024 | |
| TIL Instil Bio | Initiates: Market Perform | n/a | $24.44 | - | 1 | Nov 4, 2024 | |
| SMMT Summit Therapeutics | Initiates: Market Outperform | $32 | $18.58 | +72.23% | 1 | Nov 4, 2024 | |
| BGNE BeiGene | Initiates: Market Outperform | $288 | $192.14 | +49.89% | 1 | Sep 18, 2024 | |
| INCY Incyte | Reiterates: Market Perform | n/a | $70.40 | - | 25 | Sep 17, 2024 | |
| STRO Sutro Biopharma | Reiterates: Market Outperform | $17 | $2.62 | +548.85% | 8 | Sep 16, 2024 | |
| PRLD Prelude Therapeutics | Reiterates: Market Outperform | $7 | $0.94 | +643.65% | 2 | Sep 16, 2024 | |
| BCYC Bicycle Therapeutics | Reiterates: Market Outperform | $32 | $20.10 | +59.20% | 11 | Sep 16, 2024 | |
| BCAB BioAtla | Reiterates: Market Outperform | $5 | $1.40 | +257.27% | 8 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $6 | $1.53 | +292.16% | 5 | Aug 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $32 | $10.08 | +217.46% | 7 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $15 → $2 | $1.04 | +92.31% | 4 | Jul 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | n/a | $13.81 | - | 7 | Jul 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $12 | $1.74 | +589.66% | 4 | Jun 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $25 → $23 | $8.35 | +175.53% | 10 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $2.07 | - | 6 | Jan 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $0.95 | - | 3 | Jun 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $8 → $4 | $1.46 | +173.97% | 1 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Market Perform | n/a | $6.11 | - | 4 | Nov 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Outperform | $28 → $17 | $5.43 | +213.08% | 3 | Nov 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $2.66 | - | 2 | Dec 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $2.60 | - | 3 | Nov 15, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | n/a | $9.24 | - | 4 | Jun 14, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Market Perform | n/a | $3.28 | - | 2 | Feb 7, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $16 | $0.64 | +2,387.56% | 1 | Oct 22, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11 → $10 | $21.29 | -53.03% | 2 | Oct 12, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Outperform | $22 → $12 | $34.06 | -64.77% | 1 | Sep 25, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $11.68 | - | 1 | Nov 15, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $0.35 | - | 2 | Nov 10, 2017 |
Blueprint Medicines
Nov 18, 2024
Reiterates: Market Outperform
Price Target: $125
Current: $96.11
Upside: +30.06%
Sana Biotechnology
Nov 5, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $2.41
Upside: -
Instil Bio
Nov 4, 2024
Initiates: Market Perform
Price Target: n/a
Current: $24.44
Upside: -
Summit Therapeutics
Nov 4, 2024
Initiates: Market Outperform
Price Target: $32
Current: $18.58
Upside: +72.23%
BeiGene
Sep 18, 2024
Initiates: Market Outperform
Price Target: $288
Current: $192.14
Upside: +49.89%
Incyte
Sep 17, 2024
Reiterates: Market Perform
Price Target: n/a
Current: $70.40
Upside: -
Sutro Biopharma
Sep 16, 2024
Reiterates: Market Outperform
Price Target: $17
Current: $2.62
Upside: +548.85%
Prelude Therapeutics
Sep 16, 2024
Reiterates: Market Outperform
Price Target: $7
Current: $0.94
Upside: +643.65%
Bicycle Therapeutics
Sep 16, 2024
Reiterates: Market Outperform
Price Target: $32
Current: $20.10
Upside: +59.20%
BioAtla
Sep 16, 2024
Reiterates: Market Outperform
Price Target: $5
Current: $1.40
Upside: +257.27%
Aug 21, 2024
Reiterates: Market Outperform
Price Target: $6
Current: $1.53
Upside: +292.16%
Aug 12, 2024
Reiterates: Market Outperform
Price Target: $32
Current: $10.08
Upside: +217.46%
Jul 26, 2024
Maintains: Market Outperform
Price Target: $15 → $2
Current: $1.04
Upside: +92.31%
Jul 23, 2024
Initiates: Market Perform
Price Target: n/a
Current: $13.81
Upside: -
Jun 26, 2024
Reiterates: Market Outperform
Price Target: $12
Current: $1.74
Upside: +589.66%
Jun 20, 2024
Maintains: Market Outperform
Price Target: $25 → $23
Current: $8.35
Upside: +175.53%
Jan 5, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $2.07
Upside: -
Jun 27, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $0.95
Upside: -
Aug 8, 2022
Maintains: Market Outperform
Price Target: $8 → $4
Current: $1.46
Upside: +173.97%
Nov 12, 2020
Upgrades: Market Perform
Price Target: n/a
Current: $6.11
Upside: -
Nov 10, 2020
Downgrades: Outperform
Price Target: $28 → $17
Current: $5.43
Upside: +213.08%
Dec 3, 2019
Downgrades: Market Perform
Price Target: n/a
Current: $2.66
Upside: -
Nov 15, 2019
Downgrades: Market Perform
Price Target: n/a
Current: $2.60
Upside: -
Jun 14, 2019
Reinstates: Outperform
Price Target: n/a
Current: $9.24
Upside: -
Feb 7, 2019
Upgrades: Market Perform
Price Target: n/a
Current: $3.28
Upside: -
Oct 22, 2018
Maintains: Outperform
Price Target: $20 → $16
Current: $0.64
Upside: +2,387.56%
Oct 12, 2018
Maintains: Outperform
Price Target: $11 → $10
Current: $21.29
Upside: -53.03%
Sep 25, 2018
Downgrades: Outperform
Price Target: $22 → $12
Current: $34.06
Upside: -64.77%
Nov 15, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $11.68
Upside: -
Nov 10, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $0.35
Upside: -